Most GHRH analogs use a shortened version of the native hormone — the first 29 amino acids out of 44, because that’s where the receptor-binding activity lives. Tesamorelin takes a different approach: it uses the full 44-amino-acid sequence, modified with a trans-3-hexenoic acid group at the N-terminus for stability.
That decision to keep the full sequence — and the extensive clinical-stage research that followed — is what makes tesamorelin stand apart in the GHRH analog family. It’s one of the few research peptides in this class with a substantial body of published human data.
This compound is supplied exclusively for in vitro and preclinical research. It is not intended for human consumption, therapeutic application, or diagnostic use.
Full-Length GHRH: Why It Matters
Tesamorelin’s full 44-amino-acid sequence, developed by Theratechnologies in Montreal, includes the C-terminal region that truncated analogs like sermorelin and CJC-1295 leave out. While positions 1-29 carry the receptor binding activity, the C-terminal extension contributes to stability and may influence receptor interaction kinetics. The N-terminal trans-3-hexenoic acid modification further protects against enzymatic degradation.
Like all GHRH analogs, tesamorelin activates the GHRH receptor (GHRH-R) on pituitary somatotroph cells through the cAMP/PKA signaling pathway, stimulating pulsatile growth hormone release. The full-length structure appears to produce a GH response profile that’s been well-characterized through clinical-stage investigation.
The Visceral Fat Research
Tesamorelin’s most extensively studied application is its effect on visceral adipose tissue (VAT) — the deep abdominal fat that wraps around organs and is metabolically distinct from subcutaneous fat. VAT accumulation is associated with cardiovascular risk, insulin resistance, and inflammatory signaling. Published clinical studies reported:
- Significant VAT reduction — measured by CT imaging, not just waist circumference. This is an important distinction: waist measurements can’t differentiate between visceral and subcutaneous fat.
- Trunk fat reduction — broader decrease in abdominal adiposity beyond just the visceral compartment.
- Preserved or improved lipid parameters — triglycerides and cholesterol ratios improved in some study populations.
- Increased IGF-1 — consistent with GH axis activation, confirming the mechanism of action.
The VAT reduction was specific — lean mass was generally preserved, and subcutaneous fat showed less change than visceral fat. This selective adipose tissue targeting is what makes the metabolic research particularly interesting.
The Cognitive Research
Beyond metabolic effects, tesamorelin has generated research interest for potential cognitive effects. The GH/IGF-1 axis has well-established roles in neuroplasticity, neurogenesis, and neuroprotection. Published studies have investigated whether GH axis restoration through tesamorelin affects cognitive function in populations with GH decline.
Preliminary data has shown associations between tesamorelin treatment and improved performance on cognitive assessments, though the mechanisms — whether direct (IGF-1 crossing the blood-brain barrier and promoting neuroplasticity) or indirect (improved metabolic health → better brain function) — remain under investigation.
Tesamorelin vs Other GHRH Analogs
- vs Sermorelin: Tesamorelin has the full 44aa sequence (sermorelin has 29), the N-terminal modification for stability, and more clinical-stage data. Sermorelin has the longer research history and is more widely available.
- vs CJC-1295 no DAC: Both are protease-resistant, but through different strategies — CJC-1295 uses amino acid substitutions, tesamorelin uses the full sequence plus N-terminal modification. CJC-1295 is more commonly combined with secretagogues.
- vs CJC-1295 with DAC: DAC version produces sustained (non-pulsatile) GH elevation via albumin binding. Tesamorelin preserves natural pulsatility — different pharmacological profiles for different research questions.
Product Specifications
- Sequence: Full hGHRH(1-44) with N-terminal trans-3-hexenoic acid
- Molecular Weight: ~5,135.9 g/mol
- CAS Number: 218949-48-5
- Physical Form: Sterile lyophilized white powder
- Purity: ≥99% (verified by HPLC)
- Solubility: Soluble in bacteriostatic water
Key References
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.
- Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat. JAMA. 2014;312(4):380-389.
- Makimura H, et al. Effect of growth hormone-releasing hormone on cognitive function. Arch Neurol. 2012.
Browse Tesamorelin 10mg with verified COA from Janoshik Analytical. Compare with Sermorelin and CJC-1295, or explore our full Growth Hormone Research category.